23510-18-1

Usage

Uses

Used in Organic Synthesis:
Benzyl-(2-chloroethyl)-methyl-azanium chloride is used as a precursor for the production of quaternary ammonium salts and other related organic compounds. Its unique structure allows for versatile chemical reactions, facilitating the synthesis of a wide range of organic molecules.
Used in Pharmaceutical Synthesis:
In the pharmaceutical industry, benzyl-(2-chloroethyl)-methyl-azanium chloride serves as an intermediate in the synthesis of various drugs. Its reactivity and functional groups make it a valuable component in the development of new pharmaceutical compounds with potential therapeutic applications.
Used in Chemical Reactions as a Reagent:
Benzyl-(2-chloroethyl)-methyl-azanium chloride is employed as a reagent in chemical reactions, where its quaternary ammonium salt nature contributes to the formation of desired products. Its presence can influence reaction pathways and outcomes, making it a useful tool in the synthesis of complex organic molecules.
Potential Applications in Medicine:
Although not explicitly mentioned in the provided materials, the compound's potential applications in the field of medicine suggest that it may be used in the development of new drugs or as a precursor for pharmaceutical compounds. Its unique structure and reactivity could offer novel therapeutic opportunities, pending further research and development.

InChI:InChI=1/C10H14ClN.ClH/c1-12(8-7-11)9-10-5-3-2-4-6-10;/h2-6H,7-9H2,1H3;1H

Upstream product

• 101-98-4 2-(N-benzyl-N-methyl)amino-1-ethanol 
• 103-67-3 benzyl-methyl-amine 

Downstream Products

• 102462-14-6 1-[2-(benzyl-methyl-amino)-ethyl]-4-phenyl-piperazine 
• 13571-22-7 Propan-2-one O-[2-(benzyl-methyl-amino)-ethyl]-oxime 
• 159898-41-6 5-(Benzyl-methyl-amino)-3-(3,4-dimethoxy-phenyl)-pentan-2-one 
• 150046-78-9 2-[2-(N-Benzyl-N-methylamino)ethyl]-1,3-dihydroisoindole 
• 131099-98-4 (-)-cis-2-(4-methoxyphenyl)-3-hydroxy-5-[2-(N-benzyl-N-methylamino)ethyl]-8-chloro-2,3-dihydro-1,5-benzothiazepin-4(5H)-one perchlorate 
• 100893-18-3 (-)-cis-2-(4-methoxyphenyl)-3-hydroxy-5-[2-(N-benzyl-N-methylamino)ethyl]-8-chloro-2,3-dihydro-1,5-benzothiazepin-4(5H)-one 
• 100893-21-8 (-)-cis-2-(4-methoxyphenyl)-3-acetoxy-5-[2-(N-benzyl-N-methylamino)ethyl]-8-chloro-2,3-dihydro-1,5-benzothiazepin-4(5H)-one 
• 1254704-99-8 N₁-benzyl-N₁-methyl-N₂-phenyl-N₂-(4-(2-(pyrrolidin-1-yl)ethoxy)phenyl)ethane-1,2-diamine 
• 1253203-57-4 9-(2-(benzyl(methyl)amino)ethoxy)-7H-furo[3,2-g]chromen-7-one 
• 1226802-14-7 4-[1-[2-(benzyl-methyl-amino)-ethyl]-4-(3-chloro-4-fluoro-phenyl)-1H-imidazol-2-yl]-piperidine-1-carboxylic acid tert-butyl ester 
• 73540-31-5 7-[2-(N-benzyl-N-methylamino)ethoxy]-2,2-dimethyl-4-(2-naphthyl)-2H-chromene 
• 73540-30-4 2,2-dimethyl-4-(2-naphthyl)-7-[2-(1-piperidino)ethoxy]-2H-chromene 
• 150046-75-6 2-(N-Benzyl-N-methylamino)-1-(N-piperidinyl)ethane 
• 159898-42-7 5-(Benzyl-methyl-amino)-3-(2-bromo-pyridin-3-ylmethyl)-3-(3,4-dimethoxy-phenyl)-pentan-2-one 

Relevant academic research and scientific papers

Design, Synthesis and Preliminary Evaluation of Novel Imperatorin Derivatives as Vasorelaxant Agents

A series of novel imperatorin derivatives were synthesized from commercially available xanthotoxin. The in vitro pharmacological evaluation indicated that all of the compounds possessed potent vasodilatory activity. Among them, compounds (5b), (5d) and (5e) exhibited higher vasdilatory activity (with EC50 values of 0.68 μM, 0.59 μM and 0.49 μM, respectively) than imperatorin (EC50 = 1.12 μM). The program Volsurf was used to predict the derivatives' ADMErelevant descriptors. The results suggested that these novel compounds had a potential interest for the development of novel and potent vasorelaxant agents.

AKT AND P70 S6 KINASE INHIBITORS

The present invention provides AKT and p70 S6 kinase inhibitors of the formula: The present invention also provides pharmaceutical compositions comprising compounds of Formula I, uses of compounds of Formula I and methods of using compounds of Formula I.

Diaryldiamines with dual inhibition of the histamine H3 receptor and the norepinephrine transporter and the efficacy of 4-(3-(methylamino)-1- phenylpropyl)-6-(2-(pyrrolidin-1-yl)ethoxy)naphthalen-1-ol in pain

A series of compounds was designed as dual inhibitors of the H3 receptor and the norepinephrine transporter. Compound 5 (rNET Ki = 14 nM; rH3R Ki = 37 nM) was found to be efficacious in a rat model of osteoarthritic pain.

MACROCYCLIC INDOLE DERIVATIVES FOR THE TREATMENT OF HEPATITIS C INFECTIONS

A class of macrocyclic compounds of formula (I), wherein R7, R9, B, F, M, Q, W, Y and Z are defined herein, that are useful as inhibitors of viral proteases, particularly the hepatitis C virus (HCV) NS3 protease, are provided. Also p

6-Substituted 6H-dibenzo[c,h][2,6]naphthyridin-5-ones: Reversed lactam analogues of ARC-111 with potent topoisomerase I-targeting activity and cytotoxicity

6-Substituted 8,9-dimethoxy-2,3-methylenedioxy-6H-dibenzo[c,h][2,6] naphthyridin-5-ones were synthesized and evaluated for topoisomerase I-targeting activity and cytotoxicity. Several of these reversed lactam analogues of ARC-111 exhibited exceptional cyt

Structure-activity relationships of dimethindene derivatives as new M2-selective muscarinic receptor antagonists

A series of 2,3-disubstituted indenes, which are analogues of the widely used histamine H1 receptor antagonist dimethindene, have been synthesized and studied as muscarinic and histamine receptor antagonists. The affinities of these compounds for the five human muscarinic receptor subtypes (M1-M5) and for human histamine H1 receptors were determined in radioligand binding studies using membranes from transfected Chinese hamster ovary (CHO) cells and [3H]N-methylscopolamine ([3H]NMS). The results demonstrate that the diisopropyl analogue 19 has a similar high affinity as (S)-dimethindene at M2 receptors ((S)-dimethindene: pKi = 7.52; (-)-19: pKi = 7.37) with an improved selectivity pattern ((S)-dimethindene: M2/M1 = 6-fold, M2/M3 = 5-fold, M2/M4 = 10-fold, M2/M5 = 25-fold; (-)-19: M2/M1 = 36-fold, M2/M3 = 96-fold, M2/M4 = 42-fold, M2/M5 = 275-fold). In addition, compound (-)-19 showed 35-fold lower affinity at histamine H1 receptors (pKi = 5.61) than (S)-dimethindene (pKi = 7.16). Another interesting compound is the fluoroethyl derivative 20 (pKi/M2 = 7.49), which also exhibits a higher M2 selectivity (M2/M1 = 19-fold; M2/M3 = 22-fold; M2/M4 13-fold; M2/M5 = 62-fold) than (S)-dimethindene. Unfortunately, compound 20 also shows a high affinity for histamine H1 receptors (pKi = 8.14). The compound with the highest affinity for M2 receptors (pKi = 7.91), the dimethylaminomethylene analogue 31, displayed only a small preference for M2 receptors. In conclusion, compound (-)-19 might be useful to test the hypothesis that blockade of muscarinic M2 receptors in the brain is a viable mechanism by which to produce improved cognition. This second-generation dimethindene analogue might also be the starting point for the development of M2-selective muscarinic antagonists useful for quantifying M2 receptors in the central nervous system with positron emission tomography imaging.

Control of aminophosphine chelate ring-opening in Pt(II) and Pd(II) complexes: Potential dual-mode anticancer agents

We show that bis(aminophosphine) complexes of the type [M(R1R2N(CH2)nPPh2)2 ]2+, M = Pt(II) or Pd(II), can exist in chelate ring-closed and ring-opened forms both in the solid state and in aqueous solution. The equilibrium between them in solution can be controlled by the nature of the groups R1 and R2 (H, Me, Bz, cyclohexyl), by the bridge length n, and by the pH and Cl- concentration. X-Ray crystal structures are reported for the ring-closed complexes cis-[Pt(H2N(CH2)2PPh2-P,N)2 ]Cl2, cis-[Pt(H2N(CH2)3PPh2-P,N)2 ]Cl2, and cis-[Pt(Me(H)N(CH2)2PPh2-P,N)2][HCl 2]2, the mono-ring-opened complex cis-[Pd(Me2N(CH2)2PPh2-N,P)Cl(Me 2NH(CH2)2PPh2-P)](NO3) 2, the di-ring-opened complex cis-[Pt(Me2N(CH2)3PPh2-P)2 CL2], and, for comparison, the monochelate cis-[Pd(Me2N(CH2)3PPh2-N,P)CL2 ]. These square-planar complexes exhibit varying degrees of distortion and variable M-N bond lengths dependent not only on the trans influence of P but also on steric effects within the complex, pH-induced chelate ring-opening of cis-[Pt(Me2N(CH2)2PPh2-P,N)2 ]CL2 had an associated pK value of 6.9. In contrast, complexes with R1 and R2 = H, n = 2 or 3 or R1 = H and R2 = Me, n = 2, are more difficult to ring-open. Thus the complexes cis-[Pt(Me(H)N(CH2)2-PPh2-P,N)2]CL 2 and cis-[Pt(H2N(CH2)3PPh2-P,N)2 ]CL2, had associated pK values of 2.1 and 2.9, respectively. These aminophosphine complexes may exhibit anticancer activity by two mechanisms: by disrupting mitochondrial membrane potentials as bis-chelated (ring-closed) lipophilic cations, or by direct binding to DNA bases as ring-opened complexes.

2-(aminoalkoxy) phenylalkylamines with antiinflammatory activity

Compounds of the formula I STR1 including pharmaceutically acceptable salts thereof are disclosed in which R1, R2, R3, and R4 independently represent hydrogen, hydroxy, halo, halogenated alkyl, halogenated alkox

Imidazolyl/benzimidazolyl-terminated alkylamino ethynyl alanine amino diol compounds for treatment of hypertension

Compounds characterized generally as imidazolyl/benzimidazolyl-terminated alkylamino ethynyl alanine amino diol derivatives are useful as renin inhibitors for the treatment of hypertension. Compounds of particular interest are those of Formula I STR1 wher

PIPERIDINYL-TERMINATED ALKYLAMINO ETHYNYL ALANINE AMINO DIOL COMPOUNDS FOR TREATMENT OF HYPERTENSION

Compounds characterized generally as piperidinyl-terminated alkylamino ethynyl alanine amino diol derivatives are useful as renin inhibitors for the treatment of hypertension. Compounds of particular interest are those of Formula I STR1 wherein A is selec